COMPANY PROFILE

Bonti

Explore full profile

Biotechnology company based in orange, california

Newport Beach, United StatesFounded 2015Biotech & Life Sciences

Valuation $100–250M Last recorded · 2018

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Bonti

Bonti operates in the biopharmaceutical sector, focusing on developing innovative treatments for various medical conditions. The company primarily serves patients suffering from atopic dermatitis and pediatric spasticity, among other conditions. Bonti's business model revolves around extensive research and development (R&D) to create effective therapies, which are then brought to market following rigorous clinical trials and regulatory approvals. Revenue is generated through the sale of these approved treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies. The market Bonti operates in is highly regulated and competitive, requiring continuous innovation and adherence to strict legal standards. The company aims to improve patient outcomes through cutting-edge biopharmaceutical solutions.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2015
Headquarters: Newport Beach, United States
Open positions: None listed
Dealroom signal: 57.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Sep 2018	$195M	$195M	Allergan	—
SERIES C✓Equity / VC	Jan 2018	$16M	$62M	City Hill Ventures	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Bonti website traffic

Latest recorded traffic for Bonti is 0 monthly website visits.

Latest monthly visits0

Monthly website visitsOct 2017–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed	—	$1.1M	$4.4M
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational
EBEligo BioscienceEligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing	Paris, France	Operational
LTLiMM TherapeuticsDeveloper of antibiotics and immunomodulators, harnessing harnessing the molecular cross-talk between neuronal and innate lymphoid cells	Paris, France	Closed